Neuroscience

#Biotechnology #Concussion #Neurology #Neuroscience #Oxeia Biopharmaceuticals #University of Kansas Medical Center (KUMC)

“Game changing” concussion drug study shows positive early results  

Oxeia Biopharmaceuticals, a clinical stage biotech company developing a drug treatment for concussion to address underlying neuro-metabolic dysfunction and axonal injury, has announced “game-changing” results of a Phase IIa pilot study of OXE103 at the University of Kansas Medical Center (KUMC).   The study results suggest a potentially… Read More

#News

Active nerve cells
#Drug discovery #Neurodegenerative disorders #Neuroinflammation #Neurology #Neuroscience #Webinar

Innovative advances in neuroscience: Secure your place

It’s less than one week now till our exclusive online event ‘Innovative advances in neuroscience’, hosted by DDW and sponsored by ACRO Biosystems. Register now to secure your place on 8 November 2023 at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. You… Read More

Webinar date:
#News

#Biomarkers #Drug discovery #Neurodegenerative disorders #Neuroscience

Could NfL accelerate drug development for neurodegenerative diseases?

Listen to this article on the DDW Podcast: Professor Andy Whiting and Dr Tony Lockett discuss how specific levels of a protein could be used to advance drug development in neurodegenerative diseases. Neurofilament light (NfL) analysis is a potential biomarker for damage to both the central and peripheral nervous system. It… Read More

#Exclusive Content

Neurons
#Drug discovery #Neurodegenerative disorders #Neuroinflammation #Neurology #Neuroscience #Webinar

Innovation in neuroscience: Hear from the experts

Register now to hear from neuroscience industry experts at ‘Innovative advances in neuroscience’, hosted by DDW and sponsored by ACRO Biosystems. The online event will be free to attend on 8 November 2023 at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. You… Read More

Webinar date:
#News

CRISPR-ready neurons
#bit bio #CRISPR #Gene editing #Genetics / genomics #Neurology #Neuroscience

New CRISPR-ready neurons could democratise genomics

bit.bio has launched the first offering from its new product range ioCRISPR-Ready Cells, which allow research and drug discovery scientists to knockout any gene of interest in glutamatergic neurons. CRISPR-Ready ioGlutamatergic Neurons are first-in-class stem-cell derived human neurons containing a constitutively-expressed Cas9 nuclease for gene knockouts… Read More

#News

Neurons
#Drug discovery #Neurodegenerative disorders #Neuroinflammation #Neurology #Neuroscience #Webinar

Discover the latest advances in neuroscience

Register now to join this unique online event. Hosted by DDW and sponsored by ACRO Biosystems, ‘Innovative advances in neuroscience’ will be free to attend on 8 November 2023 at 7AM PST / 10AM EST / 3PM GMT / 4PM CET. You will hear from Fiona… Read More

Webinar date:
#News

Blood samples in lab
#Alzheimer's #Biomarkers #Diagnostics #Neurodegenerative disorders #PharmaKure

Novel blood test identifies Alzheimer’s risk with 97% accuracy

A new blood test has been shown to identify biomarkers for Alzheimer’s disease, providing an early warning of cognitive decline. Early results from PharmaKure, a pharmaceutical company spun out from The University of Manchester, UK, shows a novel whole blood test (ALZmetrix) developed by the company… Read More

#News #Trending News

MRI of the brain
#Alzheimer's #AstronauTx #Financing #Neurodegenerative disorders #University College London

UCL spinout raises £48m funding for new approach to Alzheimer’s

University College London (UCL) spinout AstronauTx has closed a £48m ($61m) Series A financing to develop novel treatments for Alzheimer’s disease and other neurodegenerative disorders. The company was launched in 2019, initially to build on research from the Alzheimer's Research UK UCL Drug Discovery Institute (UCL DDI). Protoplasmic astrocytes play… Read More

#Business & Investment #News

Active nerve cells
#Drug discovery #Neurodegenerative disorders #Neuroinflammation #Neurology #Neuroscience #Webinar

New online event: Innovative advances in neuroscience

Hosted by DDW and sponsored by ACRO Biosystems, ‘Innovative advances in neuroscience’ will be free to attend on 8 November 2023 at 7AM PDT / 10AM EST / 3PM GMT / 4PM CET. Join this free webinar to learn about innovation taking place… Read More

Webinar date:
#News

Parkinson's disease
#Gain Therapeutics #Genetics / genomics #Neurodegenerative disorders #Neuroscience #Parkinson's #Phase I trial

Allosteric therapy targets common genetic cause of Parkinson’s

Gain Therapeutics has initiated a Phase I clinical trial of GT-02287, the company’s lead drug candidate for the treatment of GBA1 Parkinson’s disease. Preclinical data demonstrated that GT-02287 can restore the function of the lysosomal enzyme glucocerebrosidase (GCase), which becomes misfolded and dysfunctional due to a… Read More

#News

World Mental Health Day
#Depression #Drug discovery #Major depressive disorder #Mental health #Postpartum depression

World Mental Health Day 2023: Drug discovery breakthroughs

Over recent months, there have been a number of ground-breaking discoveries in drug discovery for mental health conditions. A new class of antidepressants In July 2023, AlzeCure Pharma published the results of a preclinical study supporting the antidepressive effects ACD856, the first in a new class… Read More

#Editor's Choice #News

CRISPR gene editing
#CRISPR #Funding #Genetics / genomics #National Institutes of Health (NIH) #Neuroscience #Yale University

NIH awards ‘bench-to-bedside’ grant for CRISPR drug development

The National Institutes of Health has awarded the first phase of a roughly $40m grant to Yale University to advance a novel CRISPR-based gene-editing delivery platform for the targeted treatment of neurogenetic diseases. The two diseases being targeted in the project are Angelman syndrome and H1-4… Read More

#News

Eye
#AMD #Drug targets #Louisiana State University #Neuroscience #Ophthalmology

Discovery provides new therapeutic approaches to AMD

New research suggests that age-related macular degeneration (AMD) decreases an essential fatty acid, preventing the formation of a class of protective molecules and reducing repair potential – a discovery that may open new therapeutic avenues for AMD. The study shows that AMD decreases peripheral retinal docosahexaenoic… Read More

#News

Human brain
#Depression #Genetics / genomics #Korea #Major depressive disorder #Mouse models #Neuroscience

Researchers uncover molecular pathways underlying depression

Scientists have discovered the link between gene expression, DNA methylation, and brain structural changes in depression, revealing new potential therapeutic targets. By analysing gene interactions in mice subjected to behavioural tests, the researchers from Korea University Anam Hospital, Konkuk University, and Sahmyook University identified 141 genes… Read More

#News

Human brain
#Alzheimer's #Artificial intelligence (AI) #Insilico Medicine #Neurodegenerative disorders #Omics #University of Cambridge

Study finds new therapeutic targets for neurodegenerative disease

AI-driven drug discovery company Insilico Medicine and the University of Cambridge have discovered an approach to identify therapeutic targets for human diseases associated with protein phase separation (PPS). In this study, the researchers combined Insilico’s artificial intelligence (AI)-driven target identification engine PandaOmics with the FuzDrop method… Read More

#Editor's Choice #News

Seed fund
#BioInnovation Institute #Financing #Mental health #Plant-based #Start-ups

$3M funding for plant-inspired halogenated small molecule drugs

Biomia, the first company spun out from BioInnovation Institute’s Bio Studio programme, has secured $3 million in pre-seed financing from an international syndicate of investors. Biomia says it plans to use the investment to accelerate its development of plant-inspired natural and new-to-nature halogenated small molecule drug candidates and further build… Read More

#Business & Investment #News #Start-up Zone